Basilea Pharmaceutica AG Share Price Xetra
Equities
PK5
CH0011432447
Biotechnology & Medical Research
Sales 2024 * | 182M 202M 188M 15.97B | Sales 2025 * | 198M 219M 204M 17.32B | Capitalization | 471M 522M 486M 41.27B |
---|---|---|---|---|---|
Net income 2024 * | 26M 28.77M 26.81M 2.28B | Net income 2025 * | 29M 32.09M 29.9M 2.54B | EV / Sales 2024 * | 2.9 x |
Net Debt 2024 * | 56.76M 62.82M 58.53M 4.97B | Net Debt 2025 * | 12.51M 13.84M 12.9M 1.1B | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
18.4
x | P/E ratio 2025 * |
16.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 31/08/14 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 31/12/08 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 30/04/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 26/04/17 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 31/12/21 |
Director/Board Member | 69 | 08/04/13 |
1st Jan change | Capi. | |
---|---|---|
+16.48% | 45.51B | |
-9.85% | 38.52B | |
+38.08% | 38.13B | |
+28.01% | 30.74B | |
-8.64% | 26.03B | |
+11.69% | 25.92B | |
+45.14% | 14.13B | |
+33.64% | 12.73B | |
-7.81% | 11.29B |